Budesonide

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).